<DOC>
	<DOCNO>NCT02720081</DOCNO>
	<brief_summary>The purpose trial compare safety , tolerability , efficacy add MK-1029 montelukast adult persistent asthma uncontrolled receive montelukast alone . Participants specific genetic marker clinical efficacy MK-1029 .</brief_summary>
	<brief_title>Study MK-1029 Participants With Persistent Asthma That Can Be Controlled With Montelukast ( MK-1029-015 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Symptoms persistent asthma least one year History asthma treatment include `` asneeded '' inhale shortacting betaagonists ( albuterol/salbutamol ) ; stable dos inhaled corticosteroid ( ICS ) , combination ICS/longacting ( inhale ) Beta2adrenergic agonist ( LABA ) and/or oral asthma controller ( ) Must able discontinue taper asthma control medication receive Montelukast No history smoke smoke least 1 year , smoke history 10 packyears Body Mass Index ( BMI ) 15 kg/m^2 40 kg/m^2 . Females must pregnant ( negative serum human chorionic gonadotropin test ) breastfeeding must plan become pregnant duration study , include posttreatment followup period Women male participant reproductive potential must agree use adequate contraception duration study Evidence another active pulmonary disorder bronchiectasis chronic obstructive pulmonary disease ( COPD ) Unable perform acceptable , repeatable spirometry History myocardial infarction , congestive heart failure , uncontrolled cardiac arrhythmia within 3 month screen visit Major surgical procedure ( ) within 4 week screen visit Blood donation within 2 week screen visit Treatment emergency room asthma ( within 4 week ) hospitalization asthma respiratory condition within 2 month screen visit Evidence active sinus disease within 2 week screen visit Upper respiratory infection ( viral bacterial ) within 1 month screen visit History psychiatric disorder within 3 month screen visit History human immunodeficiency virus ( HIV ) Unstable disease ophthalmologic , neurological , hepatic , renal , connective tissue , genitourinary , gastrointestinal , cardiovascular hematologic system History cancer ( except successfully treat basal squamous cell carcinoma skin ) within 5 year screen visit Uncontrolled hypertension Participation clinical trial involve investigational drug within 4 week screen visit Hypersensitivity intolerance inhale betaagonists and/or leukotriene inhibitor ingredient , include lactose galactose Known sensitivity previous exposure aspirin nonsteroidal antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>